Space tourism company Virgin Galactic Holdings, Inc. (NYSE: SPCE) ended the first quarter of 2021 without generating revenue and continued the losing streak even as uncertainty over its test flight deepened after a technical glitch. The delay has come as a fresh setback to Virgin’s goal of becoming the first company to launch suborbital space tourism.
A Risky Bet?
Despite being a loss-making company, market watchers are bullish on Virgin’s stock market prospects. The shares have the potential to bounce back from the recent slump, and the low valuation makes them attractive from an investment perspective. But SPCE is not a risk-free investment and the recent fluctuations call for caution. Of late, investors have been wary of the sluggish progress in operations and growing competition.
While the company claims to have fixed the snag that forced it to postpone the test flight – originally planned for this month – there is no clarity on the next schedule. Meanwhile, the management said it would provide an update on the matter next week. Virgin’s SpaceShipTwo system is required to complete four test flights successfully before commencing commercial service. Meanwhile, company executives said their key priorities are to complete the test flight program, expand the fleet by adding new spacecraft, and develop a commercial strategy to create expanded revenue opportunities.
The Space Race
If the company encounters further delays, it might lose the first-mover advantage to rival space aspirant Blue Origin, which is owned by Amazon.com Inc (NASDAQ: AMZN) chief Jeff Bezos. Virgin’s commercial space flight, which is CEO Richard Branson’s pet project, has been in the pipeline for about 17 years now. It suffered a series of delays during that period, indicating that the project turned out to be much more difficult than initially expected. Interestingly, while Virgin missed its flight schedules, Blue Origin and Elon Musk’s SpaceX made considerable progress in their missions.
We currently expect to have a sales funnel open for a limited period of time and plan to add a finite number of incremental members to our private astronaut community. With this approach, we’ll look to build an appropriate backlog relative to the pace of our overall fleet expansion. Our goal is to address some of the consumer demand for our service while maintaining an appealing price point for the experience and an appropriate time horizon for flight for our private astronauts. We have not yet released updated pricing for our private astronaut market.Doug Ahrens, chief financial officer of Virgin Galactic
The company has not generated revenue since early last year and remained in loss during that period. In the first quarter, net loss narrowed to $0.55 per share from $1.86 per share last year but missed the estimates. It incurred an EBITDA loss of $56 million, on an adjusted basis, which marked an improvement from the previous quarter and beat the market’s forecast.
Virgin’s stock had an impressive start to 2021 and climbed to a record high of $59.41 in February. But the rally was short-lived – the shares entered a downward spiral since then and their value more than halved. The stock, which lost around 24% in the trailing six months, traded lower early Tuesday, extending the post-earnings slump.
Will the Airline Industry Evolve or Die After the Black Swan-ish Disruption?
Is the airline industry staring at an evolutionary cycle after the Coronavirus-induced Pandemic that has no parallels in the past? What was the thought process of top airline executives as Covid-19 unfolded? Were they prepared? What lies ahead? We try to find out from the treasure trove of Earnings Transcripts & Press Releases.
The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for
The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant
Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated